Korsana Biosciences, Inc. - 10-Q Filing

Korsana Biosciences reports Q3 2026 financial results featuring significant equity activity including Series B Convertible Preferred Stock and Paragon platform agreements.

SEC EDGAR ·

Tickers: $CYCN

Read the full article at SEC EDGAR

More Regulatory news